HK1079787A1 - 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物 - Google Patents

用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物

Info

Publication number
HK1079787A1
HK1079787A1 HK05112123.0A HK05112123A HK1079787A1 HK 1079787 A1 HK1079787 A1 HK 1079787A1 HK 05112123 A HK05112123 A HK 05112123A HK 1079787 A1 HK1079787 A1 HK 1079787A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
muscarinic receptor
derivatives useful
compounds
hexane derivatives
Prior art date
Application number
HK05112123.0A
Other languages
English (en)
Inventor
Anita Mehta
Arundutt V Silamkoti
Kirandeep Kaur
Jang Bahadur Gupta
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of HK1079787A1 publication Critical patent/HK1079787A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05112123.0A 2002-07-31 2005-12-29 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物 HK1079787A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/002984 WO2004014853A1 (en) 2002-07-31 2002-07-31 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
HK1079787A1 true HK1079787A1 (zh) 2006-04-13

Family

ID=31503897

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05112123.0A HK1079787A1 (zh) 2002-07-31 2005-12-29 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物

Country Status (7)

Country Link
US (1) US7265147B2 (zh)
EP (1) EP1546098B1 (zh)
AT (1) ATE396969T1 (zh)
AU (1) AU2002368152A1 (zh)
DE (1) DE60226906D1 (zh)
HK (1) HK1079787A1 (zh)
WO (1) WO2004014853A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2007039884A1 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
EP1968980A1 (en) 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
EA200801591A1 (ru) 2005-12-30 2008-12-30 Рэнбакси Лабораториз Лимитед Антагонисты мускаринового рецептора
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN102596321B (zh) * 2009-10-29 2014-11-19 詹森药业有限公司 可用作dpp-1抑制剂的炔基衍生物
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (zh) 1960-07-26
US4183857A (en) 1978-07-06 1980-01-15 Shell Oil Company 3-Benzyl-3-azabicyclo(3.1.0)hexane-2,4-dione
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0823423B1 (en) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
WO1997045414A1 (fr) 1996-05-31 1997-12-04 Banyu Pharmaceutical Co., Ltd. Derives de piperidine a disubstitution en positions 1,4
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
GB9620049D0 (en) 1996-09-26 1996-11-13 Hayles J R Repellent formulations
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
WO2004014853A1 (en) 2004-02-19
EP1546098B1 (en) 2008-05-28
US7265147B2 (en) 2007-09-04
ATE396969T1 (de) 2008-06-15
US20060122253A1 (en) 2006-06-08
AU2002368152A1 (en) 2004-02-25
EP1546098A4 (en) 2006-08-23
EP1546098A1 (en) 2005-06-29
DE60226906D1 (de) 2008-07-10

Similar Documents

Publication Publication Date Title
HK1079787A1 (zh) 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
HK1079783A1 (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
HK1085724A1 (en) 3,6-disubstituted azabicyclo 3.1.0-hexane derivatives as muscarinic receptor antagonists
EP1796678A4 (en) CARBOXAMIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EP2298744A3 (en) Opioid receptor modulators
WO2004091514A3 (en) Cgrp receptor antagonists
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2006035282A3 (en) Muscarinic receptor antagonists
RS50578B (sr) Supstituisani 2-aminotetralini za preventivni tretman parkinsonove bolesti
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006054162A8 (en) Azabicyclic muscarinic receptor antagonists
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A3 (en) Muscarinic receptor antagonists
NZ513053A (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
WO2007007281A3 (en) Muscarinic receptor antagonists
PL1753757T3 (pl) Podstawione 2,5-diamino-1H-pirole
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)